US Post News
  • Home
  • Stocks Trading
  • Analyst Snapshot
  • Market Summary
  • Financial Scores
No Result
View All Result
  • Home
  • Stocks Trading
  • Analyst Snapshot
  • Market Summary
  • Financial Scores
No Result
View All Result
US Post News
No Result
View All Result

What Is Lowering Codiak BioSciences (CDAK) Stock Pre-Market Today?

September 13, 2022
in Stocks Trading

Pre-market trading saw Codiak BioSciences Inc. (CDAK) shares lower by -20.36% to $1.33 after announcing the pricing of a public offering. It fluctuated between $1.67 and $1.7908 throughout the day and closed the last session at $1.67, down -6.70% or -$0.12.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.

Sponsored

What CDAK has announced?

A public offering of 13,333,333 shares of common stock and accompanying warrants for the purchase of 13,333,333 shares of common stock was announced by Codiak BioSciences (CDAK).

  • It is priced at $1.50 per share, with warrants accompanying each share.
  • Taking underwriting discounts and commissions into account, gross proceeds will amount to approximately $20 million.
  • CDAK is offering all of the securities.
  • A warrant with an exercise price of $1.875 per share can be exercised immediately, and it expires five years after its issuance.
  • As part of the agreement, Codiak has granted the underwriters the option to purchase up to an additional 1,999,999 shares, less underwriting discounts, and commissions, at the public offering price.
  • In accordance with customary closing conditions, the offering is expected to close on September 15, 2022.
  • As the sole book-running manager, Jefferies is managing this offering.

Updating the program

Codiak recently came reprioritizing its clinical and research initiatives, accelerating discussions relating to strategic partnerships with corporations and programs, and restructuring operations to align with a streamlined set of objectives.

Codiak has entered clinical trials for its third candidate, exoASOTM-STAT6, a systemically administered exosome-based drug candidate. Antisense oligonucleotides deliver antisense oligonucleotides to tumor-associated macrophages (TAMs) specifically to disrupt STAT6 signaling and induce antitumor immunity. In preclinical studies of aggressive hepatocellular carcinoma models, exoASO-STAT6 showed antitumor activity as a single agent.

A new partnership between Codiak and CEPI (Coalition for Epidemic Preparedness Innovations) has been announced last month to advance the company’s exoVACCTM pan betacoronavirus program. Codiak anticipates that CEPI will provide seed funding of up to $2.5 million during the first quarter of next year to fund the completion of preclinical development and identification of a clinical candidate.

Overview of the CDAK’s financial situation

Codiak had approximately $41.8 million in cash, cash equivalents, and marketable securities as of June 30, 2022. In exploring prospective funding opportunities, Codiak is proactive in extending its cash runway and potential to resource additional programs as part of its corporate and partnering discussions.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

A stock that deserves closer examination: Phunware Inc. (PHUN)

February 15, 2023

A closer look at Blue Water Vaccines Inc. (BWV) is warranted

February 24, 2023

How is EQT’s stock performing after recent trades?

March 8, 2023

“US Post News” – one of the oldest and most authoritative news sites in America. It was established in 1992, journalists, photographers, correspondents, researchers came to the publication from the editorial offices of regional newspapers, drama theater, etc. They had no training, and they gained experience and skill in the process of work.

Contact us: ceo@www.uspostnews.com

Catagories

  • Market Summary
  • Stocks Trading
  • Analyst Snapshot
  • Financial Scores

Company

  • Home
  • About US
  • Contact US

RECENT POSTS

  • The Battle of Fundamentals and Techniques: Bloom Energy Corporation (BE)
  • There Are Mixed Signals on the Chart for Sea Limited (SE)
  • Introducing Our Rant Against SoFi Technologies Inc.

Copyright © 2022 US Post News

No Result
View All Result
  • About US
  • Contact US
  • Home

Copyright © 2022 US Post News